5 unknown, 3 completed, 2 active not recruiting, 1 enrolling by invitation. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Unknown 5, Completed 3, Active not recruiting 2, Enrolling by invitation 1, Recruiting 1, Withdrawn 1 |
Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients Surovatamig, R-CHOP, R-CVP - Untreated Follicular Lymphoma | Phase 3 | Recruiting | AstraZeneca | 1018 | 2024-08-07 | 2026-10-21 |
| A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse | Phase 3 | Enrolling by invitation | Second Affiliated Hospital of Nanchang University | 80 | 2024-07-01 | 2026-01-16 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 109 | 2023-10-02 | 2026-04-17 |
| A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma Orelabrutinib and R-CHOP, R-CHOP - Treatment-naїve Mantle Cell Lymphoma | Phase 3 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 3 | 2021-12-22 | 2026-03-31 |
| Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A) - Follicular Lymphoma | Phase 3 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 605 | 2021-12-01 | 2026-06-26 |
| A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients G-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma, Unspecified Site | Phase 3 | Unknown | Nanjing Yoko Biomedical Co., Ltd. | 360 | 2018-12-28 | 2024-02-20 |
| Thalidomide Combined With R-CHOP in Newly Diagnosed,Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients Thalidomide combined with R-CHOP, R-CHOP - Thalidomide | Phase 3 | Unknown | Fudan University | 162 | 2017-08-22 | 2017-10-24 |
| R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL R-CHOP, R-CHOP / R-HAD, Rituximab - Mantle Cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 623 | 2013-11-01 | 2025-03-05 |
| Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (R-)CHOP protocol, B-ALL protocol - Lymphoma, High-grade | Phase 3 | Completed | University Hospital, Essen | 1073 | 2007-11-01 | 2017-05-05 |
| Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma R-CVP, R-CHOP, R-FM - Follicular Lymphoma | Phase 3 | Unknown | Fondazione Italiana Linfomi - ETS | 534 | 2005-12-01 | 2011-02-15 |
| Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Rituximab, Cyclophosphamide, Doxorubicin - Lymphoma, Mantle-Cell | Phase 3 | Unknown | European Mantle Cell Lymphoma Network | 360 | 2004-07-01 | 2012-09-10 |
| Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL Rituximab, Cyclophosphamide, Doxorubicin - Lymphoma, Mantle-Cell | Phase 3 | Unknown | European Mantle Cell Lymphoma Network | 570 | 2004-01-14 | 2017-03-07 |
| R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL R-CHOP, Radiotherapy - Diffuse Large B-cell Lymphoma | Phase 3 | Withdrawn | Asan Medical Center | 2016-02-23 |
Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (2) · Recurrence (1)
European Mantle Cell Lymphoma Network (2) · Fondazione Italiana Linfomi - ETS (2) · Asan Medical Center (1) · AstraZeneca (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Fudan University (1) · Nanjing Yoko Biomedical Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Second Affiliated Hospital of Nanchang University (1) · The Lymphoma Academic Research Organisation (1) · University Hospital, Essen (1)
China (5) · Germany (5) · Poland (5) · France (4) · Italy (4) · Czechia (3) · South Korea (3) · Spain (3) · Australia (2) · Belgium (2) · Canada (2) · Denmark (2) · Hungary (2) · Netherlands (2) · Taiwan (2)
Chan Cheah, MBBS FRACP FRCPA DMSc (1) · Fang-Fang Lv (1) · Hanneke C. Kluin-Nelemans, PhD (1) · Johanna Cornelia Kluin-Nelemans, Prof. Dr. (1) · Martin Dreyling, PhD (1) · Martin Dreyling, Prof. Dr. (1) · Massimo Federico, PhD (1) · Olivier Hermine, PhD (1) · Stefano Luminari, MD (1) · Ulrich Duehrsen, Prof. Dr. (1) · Vincent Ribrag, Dr (1) · Wolfgang Hiddemann, PhD (1)
PMID 20032498, PMID 24687837, PMID 19863177, PMID 20644097, PMID 22873532, PMID 25596266, PMID 26022239, PMID 27313086, PMID 29095677, PMID 29750632, PMID 30125215, PMID 31710995, PMID 31804876, PMID 32022621, PMID 33928400, PMID 34708297, PMID 36469833, PMID 37992261, PMID 40397196, PMID 40453056
2023 (2)